secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-065234
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics stockholders approve reverse stock split at ratio from 1:2 to 1:30
--------------------------------------------------------------------------------

- Stockholders approved reverse stock split at ratio between 1:2 and 1:30, board to set exact ratio and timing.
- Proposal passed with 55,438,144 votes for, 1,521,271 against, 33,539 abstaining, no broker non-votes.
- Adjournment proposal also approved with 55,461,067 for, 1,491,733 against, 40,154 abstaining.
- Special meeting held on February 23, 2026; both proposals received overwhelming stockholder support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526065234/0001193125-26-065234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526065234/xlo-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-065234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer